Sugi Predict

Sugi Predict / Compounds / SCHEMBL16059706

SCHEMBL16059706

SCHEMBL16059706

CCOC(=O)c1c(F)cnn1-c1ccc(Br)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ TSHR P16473 1/20 0.50
▸ SLC5A1 P13866 1/20 0.48
▸ SLC5A2 P31639 1/20 0.48
▸ RAB9A P51151 3/20 0.48
▸ HPGD P15428 2/20 0.45
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA4 P22748 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ MAPT P10636 3/20 0.43
▸ DUSP3 P51452 1/20 0.42
▸ HTT P42858 2/20 0.42
▸ NPBWR1 P48145 1/20 0.42
▸ MCHR1 Q99705 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22230641 0.86 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2TSHRSLC5A1SLC5A2
SCHEMBL20027937 0.86 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2TSHRRAB9AHPGD
SCHEMBL16060546 0.84 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2TSHRSLC5A1SLC5A2
SCHEMBL16060929 0.84 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2TSHRSLC5A1SLC5A2
SCHEMBL16061053 0.79 NPC1 (0.41) ALDH1A1SMN1; SMN2RAB9AHPGDCA1
SCHEMBL8339357 0.78 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2TSHRSLC5A1SLC5A2
SCHEMBL24304007 0.76 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2TSHRSLC5A1SLC5A2
SCHEMBL17091169 0.76 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2TSHRRAB9AHPGD
SCHEMBL4948312 0.76 ALDH1A1 (0.81) ALDH1A1SMN1; SMN2TSHRRAB9AHPGD
SCHEMBL19692480 0.76 TRPC1 (0.66) ALDH1A1SMN1; SMN2TSHRRAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118290357-A Heterocyclic compounds useful in the treatment of disease 艾匹根生物技术有限公司 2024-07-05 — — CN disclosed
CN-112424174-B Heterocyclic compounds useful in the treatment of disease 艾匹根生物技术有限公司 2024-02-27 — — CN disclosed
US-20230286928-A1 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE EPIGEN BIOSCIENCES, INC. (US) 2023-09-14 — — US disclosed
US-11427552-B2 Heterocyclic compounds useful in the treatment of disease EPIGEN BIOSCIENCES, INC. (US) 2022-08-30 — — US disclosed
CN-105142635-B Heterocyclic compounds useful for the treatment of diseases 艾匹根生物技术有限公司 2021-07-27 — — CN disclosed
EP-3807254-A1 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE Epigen Biosciences, Inc. (US) 2021-04-21 — — EP disclosed
CN-112424174-A Heterocyclic compounds useful for the treatment of diseases 艾匹根生物技术有限公司 2021-02-26 — — CN disclosed
EP-2988743-B1 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE EPIGEN BIOSCIENCES INC (US) 2020-12-09 — — EP disclosed
US-20200181099-A1 Heterocyclic Compounds Useful In The Treatment Of Disease EPIGEN BIOSCIENCES, INC. (US) 2020-06-11 — — US disclosed
US-10570103-B2 Heterocyclic compounds useful in the treatment of disease EPIGEN BIOSCIENCES, INC. (US) 2020-02-25 — — US disclosed
US-20190135767-A1 Heterocyclic Compounds Useful In The Treatment Of Disease EPIGEN BIOSCIENCES, INC. (US) 2019-05-09 — — US disclosed
US-20180297962-A1 Heterocyclic Compounds Useful In The Treatment of Disease EPIGEN BIOSCIENCES, INC. (US) 2018-10-18 — — US disclosed
US-10000459-B2 Heterocyclic compounds useful in the treatment of disease EPIGEN BIOSCIENCES, INC. (US) 2018-06-19 — — US disclosed
EP-2988743-A2 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE Epigen Biosciences, Inc. (US) 2016-03-02 — — EP disclosed
US-20160024031-A1 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE EPIGEN BIOSCIENCES, INC. (US) 2016-01-28 — — US disclosed
WO-2014145873-A2 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE EPIGEN BIOSCIENCES, INC. (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190135767-A1 Heterocyclic Compounds Useful In The Treatment Of Disease LPAR1, LPAR2, LPAR4 ALDH1A1 2204/4885SMN1; SMN2 1124/4885TSHR 1508/4885
US-20180297962-A1 Heterocyclic Compounds Useful In The Treatment of Disease LPAR1, LPAR4, LPAR2 ALDH1A1 1649/4885SMN1; SMN2 1820/4885TSHR 1138/4885
US-10000459-B2 Heterocyclic compounds useful in the treatment of disease LPAR1, LPAR4, LPAR3 ALDH1A1 1693/4885SMN1; SMN2 1272/4885TSHR 722/4885
US-11427552-B2 Heterocyclic compounds useful in the treatment of disease LPAR1, LPAR4, LPAR3 ALDH1A1 1693/4885SMN1; SMN2 1272/4885TSHR 722/4885
US-20160024031-A1 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE LPAR1, LPAR4, LPAR3 ALDH1A1 1621/4885SMN1; SMN2 1230/4885TSHR 708/4885
US-20200181099-A1 Heterocyclic Compounds Useful In The Treatment Of Disease LPAR1, LPAR4, LPAR3 ALDH1A1 1693/4885SMN1; SMN2 1272/4885TSHR 722/4885
US-10570103-B2 Heterocyclic compounds useful in the treatment of disease LPAR1, LPAR2, LPAR4 ALDH1A1 2204/4885SMN1; SMN2 1124/4885TSHR 1508/4885
US-20230286928-A1 HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE LPAR1, LPAR2, LPAR4 ALDH1A1 2298/4885SMN1; SMN2 1508/4885TSHR 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.